Varespladib
- Generic Name
- Varespladib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20N2O5
- CAS Number
- 172732-68-2
- Unique Ingredient Identifier
- 2Q3P98DATH
- Background
Varespladib has been investigated for the treatment and prevention of Sickle Cell Disease, Vaso-occlusive Crisis, and Acute Coronary Syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: Varespladib (A-002)Drug: placebo
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2009-10-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 164
- Registration Number
- NCT00533039
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath